Dimerix (ASX:DXB) may receive "commercial incentives" if its ongoing clinical trial on its DMX-200 drug for focal segmental glomerulosclerosis, a form of kidney disease, becomes successful, Euroz Hartleys said in a Thursday note.
The biotechnology firm opened its first pediatric site for the trial in Mexico, with 14 other pediatric sites set to open in the UK, the US, Argentina, and Brazil.
The investment firm said that if the pediatric segment of the study becomes successful, the drugmaker may be able to market and sell the medication to both pediatric and adult patients in key global markets, including Europe and the US.
Euroz Hartleys maintained its speculative buy rating and AU$0.86 price target on Dimerix.
Dimerix shares fell past 4% in recent Friday trade.
Price (AUD): $0.42, Change: $-0.02, Percent Change: -4.14%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。